Bayer Aktienges ADR (BAYRY)

$13.77 +0.36 (2.68%)
Market Cap 52.70B
Revenue (ttm) 50.43B
Net Income (ttm) -2.76B
EPS (ttm) N/A
PE Ratio 9.41
Forward PE 9.02
Profit Margin -5.48%
Debt to Equity Ratio 1.33
Volume 1,003,500
Avg Vol 880,272
Day's Range N/A - N/A
Shares Out 3.93B
Stochastic %K 96%
Beta 0.68
Analysts Strong Sell
Price Target $14.18

Company Profile

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equ...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 49 214 30 1
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany
OldHam
OldHam Jun. 10 at 5:00 PM
$BAYRY 1st opinion tomorrow?
0 · Reply
Suite510
Suite510 Jun. 4 at 5:20 PM
$BAYRY $JNJ $KVUE $SPX You ready? 🤠🍿 June 03, 2026 'This Is Their Document': Jury Told J&J Docs Prove Talc Lies Counsel for the families of three women who died of ovarian cancer delivered closing arguments Wednesday in their six-week-long bellwether lawsuit against Johnson & Johnson, telling jurors that decades-old internal documents prove the company hid that its talc was contaminated with asbestos.
1 · Reply
Suite510
Suite510 Jun. 2 at 8:12 PM
$BAYRY $JNJ $KVUE Get ready JNJ your up next with 67,000 lawsuits for Talc Cancer Deaths the largest MDL in the USA! Clock is ticking nowhere to hide 🙈 “Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement”
1 · Reply
HereForFunsies
HereForFunsies Jun. 2 at 11:30 AM
$BAYRY something is off. A settlement in the state where the most Roundup legal cases are...where Bayer is headquartered for the US...makes sense. Moving the settlement to a judge that has publicly displayed his distaste for Roundup seems like the surefire legal way to shoot all of this down. How is this even legal? Lol. Reminiscent of the lost Roundup trials where Bayer isn't allowed to use EPA rulings because the judge doesn't believe the EPA findings lol We'll see y'all. This is some bad bad news. https://www.investing.com/news/stock-market-news/bayers-725-bln-roundup-settlement-hits-fresh-legal-obstacle-shares-fall-4721203
0 · Reply
HereForFunsies
HereForFunsies Jun. 1 at 7:15 PM
$BAYRY what can you do? Sure would love to hold the 10.10s area or we're touching upper 9s again 😬
0 · Reply
flychicken1991
flychicken1991 May. 30 at 9:41 PM
$BAYRY impact map: Bayer says ASCO 2026 Phase II ARACOG data showed NUBEQA had less cognitive decline than enzalutamide in advanced prostate cancer. Direct read is differentiation for darolutamide; watch safety detail, oncologist reaction, label/payer commentary, and peer response. Not financial advice.
0 · Reply
HereForFunsies
HereForFunsies May. 30 at 2:18 AM
$BAYRY Ridiculous. One thing after another. Hopefully this one is squashed quickly. https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-sued-allegedly-monopolizing-us-market-gmo-corn-seeds-2026-05-27/
1 · Reply
Quantumup
Quantumup May. 22 at 3:16 PM
Truist⬆️the PT on $ABCL to $12 (was $10), reiterated at Buy and said—Clinical Signal & Platform Promise: What VMS Data Could Mean for ABCL's Next Phase $ALPMY $BAYRY Truist added—We reiterate our ABCL Buy rating following Ph1 ABCL-635 data that shows 1) target engagement and 2) clean safety profile that could support a superior safety profile vs. competitors. We look to Ph2 data (3Q26) to confirm or exceed efficacy seen with Veozah/Lynkuet and see favorable risk-reward benefit leading into the data. We believe 635 showing pbo-adjusted reductions in VMS frequency of ~20-25% and severity of ~10-15% could lead to upside potential of 20-60%+ vs. 20-40% downside from negative data (preview w/ scenario analyses). We updated our model to include a VMS revenue build (vs. prior project fee), reflecting how we think investors will view the stock.
0 · Reply
sideload
sideload May. 21 at 3:47 PM
$BAYRY $ICU $MCK $MDT $SYK
0 · Reply
11thestate
11thestate May. 21 at 1:53 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BAYRY — how you can actually recover something, late claims are currently being accepted: https://11th.com/cases/bayer-investor-settlement
0 · Reply
Latest News on BAYRY
No data available.
OldHam
OldHam Jun. 10 at 5:00 PM
$BAYRY 1st opinion tomorrow?
0 · Reply
Suite510
Suite510 Jun. 4 at 5:20 PM
$BAYRY $JNJ $KVUE $SPX You ready? 🤠🍿 June 03, 2026 'This Is Their Document': Jury Told J&J Docs Prove Talc Lies Counsel for the families of three women who died of ovarian cancer delivered closing arguments Wednesday in their six-week-long bellwether lawsuit against Johnson & Johnson, telling jurors that decades-old internal documents prove the company hid that its talc was contaminated with asbestos.
1 · Reply
Suite510
Suite510 Jun. 2 at 8:12 PM
$BAYRY $JNJ $KVUE Get ready JNJ your up next with 67,000 lawsuits for Talc Cancer Deaths the largest MDL in the USA! Clock is ticking nowhere to hide 🙈 “Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement”
1 · Reply
HereForFunsies
HereForFunsies Jun. 2 at 11:30 AM
$BAYRY something is off. A settlement in the state where the most Roundup legal cases are...where Bayer is headquartered for the US...makes sense. Moving the settlement to a judge that has publicly displayed his distaste for Roundup seems like the surefire legal way to shoot all of this down. How is this even legal? Lol. Reminiscent of the lost Roundup trials where Bayer isn't allowed to use EPA rulings because the judge doesn't believe the EPA findings lol We'll see y'all. This is some bad bad news. https://www.investing.com/news/stock-market-news/bayers-725-bln-roundup-settlement-hits-fresh-legal-obstacle-shares-fall-4721203
0 · Reply
HereForFunsies
HereForFunsies Jun. 1 at 7:15 PM
$BAYRY what can you do? Sure would love to hold the 10.10s area or we're touching upper 9s again 😬
0 · Reply
flychicken1991
flychicken1991 May. 30 at 9:41 PM
$BAYRY impact map: Bayer says ASCO 2026 Phase II ARACOG data showed NUBEQA had less cognitive decline than enzalutamide in advanced prostate cancer. Direct read is differentiation for darolutamide; watch safety detail, oncologist reaction, label/payer commentary, and peer response. Not financial advice.
0 · Reply
HereForFunsies
HereForFunsies May. 30 at 2:18 AM
$BAYRY Ridiculous. One thing after another. Hopefully this one is squashed quickly. https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-sued-allegedly-monopolizing-us-market-gmo-corn-seeds-2026-05-27/
1 · Reply
Quantumup
Quantumup May. 22 at 3:16 PM
Truist⬆️the PT on $ABCL to $12 (was $10), reiterated at Buy and said—Clinical Signal & Platform Promise: What VMS Data Could Mean for ABCL's Next Phase $ALPMY $BAYRY Truist added—We reiterate our ABCL Buy rating following Ph1 ABCL-635 data that shows 1) target engagement and 2) clean safety profile that could support a superior safety profile vs. competitors. We look to Ph2 data (3Q26) to confirm or exceed efficacy seen with Veozah/Lynkuet and see favorable risk-reward benefit leading into the data. We believe 635 showing pbo-adjusted reductions in VMS frequency of ~20-25% and severity of ~10-15% could lead to upside potential of 20-60%+ vs. 20-40% downside from negative data (preview w/ scenario analyses). We updated our model to include a VMS revenue build (vs. prior project fee), reflecting how we think investors will view the stock.
0 · Reply
sideload
sideload May. 21 at 3:47 PM
$BAYRY $ICU $MCK $MDT $SYK
0 · Reply
11thestate
11thestate May. 21 at 1:53 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BAYRY — how you can actually recover something, late claims are currently being accepted: https://11th.com/cases/bayer-investor-settlement
0 · Reply
HereForFunsies
HereForFunsies May. 20 at 7:18 PM
$BAYRY that's some nice volume today 👀 Sure wouldn't mind this to move back upward as we wait for a SCOTUS ruling. I'll trim in the mid 12s
0 · Reply
HboFam
HboFam May. 20 at 6:25 PM
$SLS @cb5000calls $AZN and $BAYRY have to be on the short list of possible Tambiciclib suitors.
0 · Reply
HboFam
HboFam May. 20 at 6:04 PM
$AZN $BAYRY Tambiciclib Suitors
0 · Reply
Arkasha
Arkasha May. 15 at 7:28 PM
$BAYRY I just don't understand how this is still surpressed
1 · Reply
Quantumup
Quantumup May. 12 at 12:43 PM
Stifel y'day⬆️ $ABCL's PT to $8 (was $7), reit'd Buy/said it now models ABCL635 peak U.S. sales of $1.4B and $800M in menopause-related VMS and oncology-related (specifically early-stage breast cancer) VMS. $ALPMY $BAYRY Here's what Stifel said in its note: https://x.com/Quantumup1/status/2054180048857424221?s=20
0 · Reply
HereForFunsies
HereForFunsies May. 12 at 11:47 AM
$BAYRY nice earnings beat, let's go!
0 · Reply
PickAlpha
PickAlpha May. 11 at 12:00 PM
6/6: BASF commissions Ludwigshafen “BioHub” fermentation plant to make biological crop-protection actives in-house; investment cited in high double‑digit € millions. $BASFY $BAYRY $CTVA $FMC $MOS
0 · Reply
KilroyPicks
KilroyPicks May. 7 at 8:09 PM
$MIST - Top Strategic Acquires Continued Part 3 3. Bayer $BAYRY Bayer is currently refocusing its pharmaceutical division to counter the loss of revenue from Xarelto. Strategic Fit: Bayer has explicitly stated a focus on cardiovascular diseases and has been active in small-to-mid-cap M&A recently (e.g., the acquisition of Perfuse Therapeutics in May 2026). Synergy: CARDAMYST offers a "medtech-like" pharmaceutical solution (a self-administered spray) that fits Bayer’s history of specialized, high-margin cardiovascular products.
1 · Reply
HereForFunsies
HereForFunsies May. 7 at 11:25 AM
$BAYRY this thing is a yo-yo until we get clarity on litigation. One day back above 11 and the next below 🤦‍♂️
0 · Reply
sideload
sideload May. 6 at 11:36 PM
$BAYRY $ICU $MCK $MDT $SYK
1 · Reply
OldHam
OldHam Apr. 30 at 10:11 PM
$BAYRY whats likelihood we get back to $30 levels seen in 2017? What would it take to get there?
1 · Reply
scottptts
scottptts Apr. 30 at 7:52 PM
$BAYRY Not sure what changed over the past couple of days
2 · Reply